More tools:Markets·Screener·Research·Chat

Staar Surgical Co (STAA) Financial Statements

Staar Surgical Co
SIC 3851 · OPHTHALMIC GOODS
FIGI BBG001S6MC39
XNAS · usd
24.16▲ 0.69 (2.94%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close23.47
Day's Range22.66 – 24.36
52-Week Range15.59 – 35.87
Volume1.4M
Avg Volume934.6K
Share Statistics
Shares Outstanding
Employees957
ExchangeXNAS
Listed1983-07-07
Share count as of August 7, 2026
Loading Income Statement…
Key questions about Staar Surgical Co (STAA)
What is Staar Surgical Co's Market Cap?
Staar Surgical Co's Market Cap is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is Staar Surgical Co's Trailing P/E?
Staar Surgical Co's Trailing P/E is 315.6×, based on as-reported figures from SEC (XBRL) filings.
What is Staar Surgical Co's Price / Sales?
Staar Surgical Co's Price / Sales is 3.6×, based on as-reported figures from SEC (XBRL) filings.
What is Staar Surgical Co's Revenue (TTM)?
Staar Surgical Co's Revenue (TTM) is $339.6M, based on as-reported figures from SEC (XBRL) filings.
What is Staar Surgical Co's Net Income (TTM)?
Staar Surgical Co's Net Income (TTM) is $3.8M, based on as-reported figures from SEC (XBRL) filings.
What is Staar Surgical Co's EBITDA?
Staar Surgical Co's EBITDA is $22.2M, based on as-reported figures from SEC (XBRL) filings.
What is Staar Surgical Co's Diluted EPS (TTM)?
Staar Surgical Co's Diluted EPS (TTM) is 0.08, based on as-reported figures from SEC (XBRL) filings.
What is Staar Surgical Co's EBITDA Margin?
Staar Surgical Co's EBITDA Margin is 6.5%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJul 3, 2026Apr 3, 2026Jan 2, 2026Sep 26, 2025Jun 27, 2025Mar 28, 2025Dec 27, 2024Sep 27, 2024Jun 28, 2024Mar 29, 2024Dec 29, 2023Sep 29, 2023Jun 30, 2023Mar 31, 2023Dec 30, 2022Sep 30, 2022
Net sales
YoY growth+111.0%+119.6%+18.1%+6.9%
Cost of sales
Gross profit
% of revenue74.5%73.6%75.7%82.2%
Selling, general and administrative expenses:
General and administrative
Selling and marketing
Research and development
Merger transaction and related costs
Restructuring, impairment and related charges
Total selling, general and administrative expenses
Operating income (loss)
% of revenue10.8%8.5%-39.5%19.5%
Other income (expense), net:
Interest income, net
Gain (loss) on foreign currency transactions
Royalty income————
Other income, net
Total other income, net
Income (loss) before income taxes
Provision (benefit) for income taxes
Net income (loss)
% of revenue8.6%5.6%-31.7%9.4%
Basic
Diluted